Fig. 3

Effects of NCEH1 on the formation of Cav-1/eNOS in mouse aortae. (A, C) Effects of NCEH1 shRNA on the protein expression of Cav-1. (B, D) Effects of NCEH1 overexpression on the protein expression of Cav-1. (E) Effects of NCEH1 shRNA on the mRNA level of Cav-1. (F) Effects of NCEH1 overexpression on the mRNA level of Cav-1. (G) Effects of NCEH1 shRNA on the Cav-1/eNOS complex. (H) Effects of NCEH1 overexpression on the Cav-1/eNOS complex. (I, K) Effects of NCEH1 shRNA on the protein expression of Cav-1 upon HG exposure. (J, L) Effects of NCEH1 overexpression on the protein expression of Cav-1 upon HG exposure. (M, O) Effects of NCEH1 shRNA on the Cav-1/eNOS complex upon HG exposure. (N, P) Effects of NCEH1 overexpression on the Cav-1/eNOS complex upon HG exposure. n = 4. *P < 0.05 versus Con shRNA or Vector. †P < 0.05 versus NG. The P-value was calculated by unpaired two-tailed Student’s t-test (A-H). Differences between groups were assessed with ANOVA followed by Bonferroni post-hoc test (K, L,O, P). For immunoblotting assay, the ratio of the grayscale values of the target protein and β-actin in each group was normalized by the average value of the control group. For RT-PCR assay, the expression levels of the target gene were relative to β-actin and their expression was relatively quantified by the 2^−ΔΔCt method. Cav-1, caveolin-1; NCEH1, neutral cholesterol ester hydrolase 1; NG, normal glucose; HG, high glucose; OE, overexpression; eNOS, endothelial nitric oxide synthase